Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Evotec SEEVO-7.291.581.2315.97-15.62%-5.50%44.92$3.67$52.31961$3.86

Detail of Evotec SE

 
CEO
Dr. Mario Polywka DPHIL, Ph.D.
Employees
5022
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$1B

Company details

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$788.44M
Cost of goods (CoG)
-$662.45M
Gross profit (GP)
$125.99M
Operating expense (OE)
-$229.00M
Research and development (R&D)
-$66.92M
General and administrative (G&A)
-$173.32M
Other (OTH)
$11.24M
Operating income (OI)
-$78.20M
Other income expense (OIE)
-$100.33M
Pretax income (PI)
-$185.18M
Tax (TAX)
$14.49M
Net income (NI)
-$170.69M
Evotec SE
EVO • XNGS • US
$3.86
-5.15 (-57.10%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.53
Margin profit
-21.65%
52 week low
$2.89
52 week high
$11.89
50-day simple moving average
$3.61
200-day simple moving average
$3.67
Percent held by insiders
0.00%
Percent held by institutions
2.18%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
EVO -58.48%
eps change
EVO 0.00%